|
Synonyms: Rova-T | SC0001-SCX
Compound class:
Antibody
Comment: Rovalpituzumab tesirine is an antibody-drug conjugate (ADC) that was designed to exploit the expression of the NOTCH ligand DLL3 on certain tumours for anti-cancer efficacy [1]. It is a humanized anti-DLL3 monoclonal that is linked to a pyrrolobenzodiazepine dimer toxin called tesirine (or D6.5; PubChem CID 73672523). Once the ADC is internalized, its D6.5 payload is released and causes lethal DNA damage in the target cells.
|
Classification  |
|
| Compound class | Antibody |
| International Nonproprietary Names |
|
| INN number | INN |
| 10141 | rovalpituzumab tesirine |
| Synonyms |
| Rova-T | SC0001-SCX |
| Database Links |
|
| Specialist databases | |
| IMGT/mAb-DB | 569 |
| Other databases | |
| GtoPdb PubChem SID | 404859008 |
| Search PubMed clinical trials | rovalpituzumab tesirine |
| Search PubMed titles | rovalpituzumab tesirine |
| Search PubMed titles/abstracts | rovalpituzumab tesirine |
